Chart usGOLD   Chart usSILVER  
 
Food for thought
If you want a picture of the future a boot stamping on a human face. For ever. Don’t let it happen, it depends on you
George Orwell  
Search for :
LATEST NEWS  :
MINING STOCKS  :
Subscribe
Write Us
Add to Google
Search on Ebay :
PRECIOUS METALS (US $)
Gold 1216.012.41
Silver 17.02-0.13
Platinum 1262.80-16.45
Palladium 766.10-10.40
WORLD MARKETS
DOWJONES 16729-79
NASDAQ 4389-33
NIKKEI 15662-420
ASX 5299-36
CAC 40 4243-123
DAX 9196-186
HUI 1960
XAU 80-1
CURRENCIES (€)
AUS $ 1.4403
CAN $ 1.4116
US $ 1.2663
GBP (£) 0.7849
Sw Fr 1.2080
YEN 136.9450
CURRENCIES ($)
AUS $ 1.1375
CAN $ 1.1149
Euro 0.7899
GBP (£) 0.6200
Sw Fr 0.9536
YEN 108.1410
RATIOS & INDEXES
Gold / Silver71.45
Gold / Oil13.83
Dowjones / Gold13.76
COMMODITIES
Copper 3.04-0.02
WTI Oil 87.93-1.18
Nat. Gas 3.95-0.08
Market Indices
Metal Prices
RSS
Precious Metals
Graph Generator
Statistics by Country
Statistics by Metals
Advertise on 24hGold
Projects on Google Earth
Investing and Mining Stocks
Most read articles
Rick Ackerman
Using Put Options to Bet on a Junk-Bond Crash
Here’s an easy play for those who have never cashed a winning ticket trading puts or calls. Specifically, I am going to tell you how to bet on a junk-bond crash without risking your shirt — even if junk bonds continue to defy gravity indefinitely. First, let me assert that straight-up directional plays with stock options almost never win. Your odds are better trying to predict precisely when a shooting star will flash across the night sky. Similarly, if you buy call options with the expectation
Monday, September 29, 2014
The Gold Report
Chris Thompson: Gold and Silver Miners that Can Make Money Now
The Gold Report: In your previous Gold Report interview of Dec. 31, 2013, you predicted 2014 prices of $1,400 per ounce ($1,400/oz) for gold and $25/oz for silver. Do you think that gold and silver can still meet those prices this year? Chris Thompson: Those figures referred to the high side of the anticipated trading range for both metals. Today, our prediction for the high side in 2014 is $1,350/oz for gold and $22/oz for silver. In other words, we see silver potentially trading up to $22/oz
Sunday, August 17, 2014
The Gold Report
Jocelyn August: Upcoming Catalysts for Precious and Base Metals, Uranium and Oil and Gas
The Mining Report: The top catalysts Sagient Research follows tend to move resource stock prices 6 10%. What are the top three catalysts in precious metals equities? Jocelyn August: The top three catalysts for absolute movements?either up or down?in precious metals are the ones that help investors determine the potential success of a project, so we're looking at preliminary economic assessments (PEA), government approvals or permits?that's when a company actually receives the decision?and resour
Thursday, July 24, 2014
The Gold Report
Tell Us, Christos Doulis, Can Gold Act as a Safe Haven Again?
The Gold Report: The World Gold Council, which gets its numbers from Thomson Reuters GFMS, reports that total gold demand in Q2/14 fell by 15% versus the same period in 2013. Furthermore, physical bar and official coin demand were basically cut in half while jewelry demand fell by 217 tons or 30%. What do you make of all of that? Christos Doulis: Clearly, there has been less enthusiasm for owning gold in recent years. A lot of that has to do with the concept of gold as a safe haven. Six years a
Monday, September 22, 2014
The Gold Report
Richard Karn's Advice for Avoiding the Walking Dead
The Gold Report: When we interviewed you in April, you said the pending demise of zombie companies on the Australian Stock Exchange (ASX) was a good thing because there were too many deadbeats in the specialty metal sector. Has that process worked its way through the system or are there still some "walking dead" making it difficult for investors to pick out the promising companies? Since then another 23 resource companies have failed, and as of Aug. 25, 2014, 17 more had not paid their listin
Wednesday, September 24, 2014
The Gold Report
Miners Must Control Costs to Improve Share Prices: Byron King
The Gold Report: Byron, gold is above $1,300/ounce ($1,300/oz)?although not by much?and silver topped $20/oz. What was holding their prices down, and what are the fundamentals that will move the prices going forward? Byron King: The short answer is that, for all its faults, the dollar has strengthened, which holds down gold and silver prices. The longer answer is that gold and silver are manipulated metals. That is, the world's central banks have an aversion to things they can't control, and on
Monday, July 28, 2014
The Gold Report
Doug Loud and Jeff Mosseri: Three Reasons Why Gold and Gold Stocks Will Rise
The Gold Report: Over two days, July 14 and 15, the price of gold fell over $40 per ounce ($40/oz), more than 3% of its value. To what do you attribute this drop? Jeffrey Mosseri: I don't think it was a very extraordinary event. Gold has been trading around $1,300/oz. We see sharp upward and downward movements triggered by, for instance, something Federal Reserve Chair Janet Yellen said or a negative report by Goldman Sachs. It looks as if gold will stay in the $1,300/oz range for a little whil
Saturday, July 26, 2014
Dennis Miller - Casey Reseach
Home Healthcare Cuts Threaten 500,000 Jobs and Put Female-Owned Businesses at Risk
That title wouldn’t make for much of a campaign slogan, and yet, it’s the natural outcome of one particular politician’s promise. As the editor of a retirement-focused newsletter, most of the notes I receive about the Affordable Health Care Act, or Obamacare, are first-person accounts of how a reader’s change in coverage or cost is affecting his finances. These (mostly sad) stories prompted several discussions with Andy Mangione, vice president of government relations of the Association of Matur
Thursday, September 25, 2014
The Gold Report
Jay Taylor Urges Investors to Stay Liquid for the Coming Gold Boom
The Gold Report: The price of gold has fallen more than $130 an ounce ($130/oz) since July. Why? Jay Taylor: I believe we have two different markets. One is an honest market for physical metal. The other is a market that has increasingly become less than honest. The latter is a paper market, primarily in London and New York, and it is used to muddy the waters of price discovery with gold and silver. This paper market price is assumed to be the real price of gold. I don't think that's true.
Tuesday, September 30, 2014
The Gold Report
Kal Kotecha: Going Against the Grain in Five Names
The Mining Report: You're the editor of Junior Gold Report, but you also follow similar-sized companies in the energy sector. Please give our readers an overview of the energy space. Kal Kotecha: I've been involved in the space since 2002 and I've never witnessed anything like what is currently happening. In the energy sector, I see the price of uranium increasing, but to see price appreciation across energy stocks, the price of oil must remain near $100 per barrel ($100/bbl). That $100/bbl ben
Tuesday, September 30, 2014
The Gold Report
Sprott Fund Manager Jason Mayer's Guide to Resource Stock Profits
The Mining Report: In February, you gave a speech at The Vancouver Club that acknowledged the impact of investor fatigue on the junior mining equity space. Seven months later, are investors starting to get excited again about the space? Jason Mayer: Investors have been reacting in fits and starts, and everyone is still very cautious. I track a number of funds, and I watch how they perform on a day-to-day basis. What I have found interesting is that a number of resource funds in Canada continue
Tuesday, September 23, 2014
The Life Sciences Report
Six Innovative Australian Opportunities from Canaccord's Matthijs Smith
The Life Sciences Report: From your investment firm's perspective in Australia, how are the life sciences performing this year? Matthijs Smith: It has been a tough year in the Australian biotech sector. At Canaccord Genuity, we run a biotech index covering the top 25 life science stocks in the country. It excludes the large caps, such as Cochlear Ltd. (COH.ASX), CSL Behring Ltd. (CSL:ASX; CMXHY:OTCPK) and ResMed Inc. (RMD:NYSE), and, instead, focuses on the innovative companies. This index is
Thursday, August 28, 2014
The Energy Report
Keep Truckin': Russell Stanley on How to Snap Up Growing Energy Services Companies
The Energy Report: Are oil and gas field services in Canada a high growth sector? Russell Stanley: Energy prices drive oil and gas field construction and infrastructure development in western Canada. Other drivers include the need to build out liquefied natural gas (LNG) facilities and rail facilities. Jennings Capital targets service companies with market caps in the $50 to $200 million ($50�200M) range. These names tend to have fewer analysts following than do the larger names. We like comp
Thursday, September 25, 2014
The Gold Report
From Beaver Creek to Denver: A Journey Between Different Worlds
Despite a relatively low gold price, 2014 marked a banner year for the Precious Metals Summit in Beaver Creek, Colorado, observed The Gold Report Publisher Jason Mallin. It topped 2013 records for attendees and presenting companies by 20%. "Nonproducing companies are still confident they can bring projects online. By starting smaller or through a strategic acquisition, they are looking for cash flow as soon as possible," Mallin observed. Meanwhile, at the Denver Gold Forum, the producing gold co
Wednesday, October 01, 2014
The Gold Report
Canaccord's Joe Mazumdar Shares His Favorite Get Rich Slow Schemes
The Gold Report: A strange thing happened over the last few months. The price of gold went down, but some of the junior mining equities are up. Can you explain what is going on? Joe Mazumdar: Year-to-date gold is flat. But the Market Vectors Junior Gold Miners ETF (GDXJ:NYSE.MKT) is up 13%. Investors prefer owning the equity now rather than owning gold. This was not the case a couple of years ago when gold was going up to $1,900 an ounce ($1,900/oz) and far outperforming equities. Part of the r
Wednesday, October 01, 2014
The Life Sciences Report
Three Biotech Investment Ideas that Disrupt and Diversify: Anita Dushyanth
The Life Sciences Report: Anita, now that the fall investment season is upon us, is it a good time to look for opportunities in the life sciences? Anita Dushyanth: Definitely yes. In 2013, the NASDAQ Biotech Index showed a gain of about 66%, and in 2014 thus far, it's been about 21%, which is not too bad. The sector has had some corrections, but it is growing. Within biotech itself, investors can consider adding small-cap companies to their portfolios, as well as established players offering n
Thursday, September 25, 2014
The Gold Report
Filipe Martins: African Miners that Can Generate Cash Flow and Dividends
The Mining Report: Some of the experts we have interviewed for the The Mining Report and The Gold Report is that a $1,250–1,350/ounce ($1,250–1,350/oz) gold price can be expected in the short term. Do you agree? Filipe Martins: At GMP, we forecast a $1,350/oz gold price from roughly 2015, but we think there is a real risk that the gold price could fall before it rises, given the threat of higher borrowing costs. Most recently, we haven't seen the increases in physical demand from China and Indi
Tuesday, September 09, 2014
The Gold Report
David Sadowski: Are You Ready for Upward Pressure on Uranium Prices?
The Mining Report: In past interviews with Streetwise Reports, you predicted that the price of uranium will rise this year. But that has not panned out. Why not? David Sadowski: Simply put, there is a short-term supply problem in the uranium industry. We believe, however, in the long term, supply will not be able to keep up with demand growth. The point at which we previously expected demand to outstrip supply has been pushed out by a couple of years. That development has impacted the price in
Sunday, August 10, 2014
The Energy Report
  How is Doug Casey Preparing for a Crisis Worse than 2008? He and His Fellow Millionaires Are Getting
The Mining Report: This year's Casey Research Summit is titled "Thriving in a Crisis Economy." What is the most pressing crisis for investors today? Doug Casey: We are exiting the eye of the giant financial hurricane that we entered in 2007, and we're going into its trailing edge. It's going to be much more severe, different and longer lasting than what we saw in 2008 and 2009. Investors should be preparing for some really stormy weather by the end of this year, certainly in 2015. TMR: The 200
Wednesday, September 03, 2014
The Life Sciences Report
Turnaround Stories Lead Reni Benjamin's Biotech Front-Runners
The Life Sciences Report: Do you have thoughts on what might move the biotech market over the remainder of the summer and through the early fall? Reni Benjamin: The biotech market was on a tear through the beginning of 2014, but due to a variety of factors it began a healthy correction at the end of February/beginning of March. One issue was drug-pricing concerns regarding Gilead Sciences Inc.'s (GILD:NASDAQ) Sovaldi (sofosbuvir), which was approved last December for the treatment of chronic he
Thursday, July 10, 2014
Richard Mills - Ahead of the Herd
Cloud Revenue Cycle Management
U.S. hospitals write off between 3% and 17% of their revenue due to denied claims from payers - insurance carriers, other third-party payers, or health plan sponsors (employers or unions) for the patient. Further, administrative and process-related inefficiencies are reducing health care cash flow, revenue is being lost that should have been collected - it’s a lot of revenue.   This “lost revenue” puts additional burden on hospitals that already are stretched due to rising healthcare costs an
Friday, August 08, 2014
The Life Sciences Report
Biotechs with Upside Possibilities Target Ebola and Liver Disease: MLV & Co.'s Vernon Bernardino
The Life Sciences Report: Vernon, up to 30 thousand (30K) people currently have a vital and pressing need for experimental therapeutic and immunization agents to protect them from the ongoing Ebola virus disease (EVD) outbreak in West Africa. That 30K is a conservative estimate, according to University of Oxford epidemiologist Oliver Brady, who wrote an op-ed piece for the World View column of Nature last month. He said even that conservative approximation far exceeds the current supplies of exp
Wednesday, September 10, 2014
The Life Sciences Report
Steve Brozak: Big-Picture Biotech Stocks Rule the Future
The Life Sciences Report: Steve, last year there were 15 new molecular entities approved by the U.S. Food and Drug Administration (FDA) through Aug. 12, 2013. So far this year, up through Aug. 19, 2014, there have been 26 new molecular entities approved. What could be contributing to this stepped-up pace of approvals? Steve Brozak: The reason is two-pronged. First, the FDA has a direct and specific mandate to increase the throughput of drug approvals. Second, the pharmaceutical industry of yest
Thursday, September 04, 2014
Oilprice.com - oilprice.com
Soros Signals Argentina’s Shale is Biggest Place to Be
One of the world's legendary investors is upping his bet on Argentina's shale oil and gas industry in a show of confidence for shale production in South America's largest unconventional prize --and a big boost for both supermajors and smaller players making big waves in the heart of new discovery areas. George Soros has doubled his stake in YPF SA, the state-owned oil company in Argentina, which sits atop some of the world's largest shale oil and gas resources, and is about to get ev
Thursday, September 04, 2014
The Gold Report
Tom Hayes' Trio of Rare Earth Project Contenders
The Mining Report: It is now known that China's State Reserve Bureau intends to begin stockpiling medium-to-heavy rare earth elements (REEs), and that China will also strengthen REE export quotas. Will these actions lead to a race to get non-Chinese REE projects into production? Tom Hayes: It will. One shouldn't view the general tightening of heavy rare earth elements (HREE) export quotas in isolation, however. It's more relevant to look at actual demand for particular REEs. About 30?40% of Chi
Tuesday, July 15, 2014
The Life Sciences Report
Bring On the Orphans: Aegis Capital's Raghuram Selvaraju Lays Out a Winning Biotech Strategy
The Life Sciences Report: Ram, it's hard to imagine a situation where orphan drugs wouldn't be reimbursed, because the needs are so great and the optics would be very bad for both payers and drug developers. These drugs range from angiogenesis inhibitor Sutent (sunitinib/Pfizer Inc. (PFE:NYSE]), which is reimbursed at $48,000 a year ($48K/year) to the monoclonal antibody Soliris (eculizumab/ Alexion Pharmaceuticals Inc. [ALXN:NASDAQ]), reimbursed at more than $500K/year. Are we going to reach a
Wednesday, August 13, 2014
James West - Midas Letter
Orbite Aluminae: Can Glencore PLC Save It?
Long suffering shareholders of Orbite Aluminae Inc. (TSX.ORT) have been roused from their collective misery recently by what appears to be a strong possibility that the company may get financing for construction of its plant from Glencore PLC (LON:GLEN). The company’s share price has been a sore point since touching a high of $3.69 a share back in September of 2012. In March of this year, the shares reached an all time low of $0.20, and many investors have thrown in the towel on the way down, ab
Wednesday, July 09, 2014
The Life Sciences Report
A Tour of Australian Biotechs with MorgansÂ? Scott Power
The Life Sciences Report: The latest Scientific American Worldview Scorecard has ranked Australia No. 7 in biotechnology in the world, up from No. 10 last year. What is Australia's secret sauce? Scott Power: In Australia, we have about 100 listed life science medical device/diagnostic companies. The sector is maturing. The weaker companies have disappeared. Well-established, sustainable businesses with approved products are generating more than enough sales to cover their operating costs. One o
Thursday, October 02, 2014
The Gold Report
Jason Hamlin Says Gold Is Unstoppable, with Stocks Leading the Way
The Gold Report: You told The Gold Report in December 2012, "I think the official inflation adjusted [gold] high of $2,400 per ounce ($2,400/oz) will be taken out within the next 12 months." Why didn't this happen? Jason Hamlin: One reason is that inflation hasn't risen significantly until lately. That is due to the recent record low velocity of money. Trillions of dollars in new money were created to stimulate the economy and get us out of the financial crisis of 2008?2009, but the banks have
Wednesday, August 06, 2014
The Life Sciences Report
Medtech Shifts from High Gear ...
The Life Sciences Report: Canaccord Genuity is an investment banking firm focused on growth companies. Can you comment generally on the outlook for medical devices? William Plovanic: I would say the medical device sector has, over the last couple of years, provided very solid returns for investors�especially in 2013. As we've moved into 2014, it's been more challenging for some of the high-growth companies. Valuations moved up significantly in 2013, and companies fundamentally did very well als
Tuesday, August 19, 2014

Advertising